Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and FLOT with Short Radiation for Locally Advanced Gastroesophageal Junction Adenocarcinoma
NCT07018570Phase 2Recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Jul 2025
- Primary completion
- Jun 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in gastroesophageal junction adenocarcinoma, sponsored by National Cancer Center Hospital East. Started Jul 2025; status: recruiting.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07018570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018570.